Filtered By:
Condition: Sickle Cell Anemia
Countries: USA Health

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 297 results found since Jan 2013.

Sickle cell disease: a comprehensive program of care from birth.
Authors: de Montalembert M, Tshilolo L, Allali S Abstract As more children are appropriately being diagnosed, the burden of sickle cell disease is increasing greatly in Africa and in high-resource countries such as the United States and Europe. Early management is mandatory, but newborn screening is not implemented everywhere. Point-of-care testing devices are increasingly being used in low-resource countries, showing good sensitivity and specificity. Because the diagnosis is often traumatic for the families, the announcement should be made by an experienced person. The development of care networks is urgently requ...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Sickle cell disease: current treatment and emerging therapies.
Abstract Sickle cell disease (SCD) is among the most common genetic diseases in the United States, affecting approximately 100,000 people. In the United States, SCD is characterized by a shortened life expectancy of only about 50 years in severe subtypes, significant quality-of-life impairments, and increased healthcare utilization and spending. SCD is characterized by chronic hemolytic anemia, vaso-occlusion, and progressive vascular injury affecting multiple organ systems. The pathophysiology is directly related to polymerization of deoxygenated hemoglobin, leading to a cascade of pathologic events including ery...
Source: The American Journal of Managed Care - October 31, 2019 Category: Health Management Authors: Neumayr LD, Hoppe CC, Brown C Tags: Am J Manag Care Source Type: research

Acute compartment syndrome in a patient with sickle cell disease.
We present a young man with HbSC disease who developed acute compartment syndrome. This is only the second report of this syndrome in a patient with HbSC disease. This is a very rare complication in HbSC disease, but it can have serious implications. PMID: 32777927 [PubMed - as supplied by publisher]
Source: Annals of the Royal College of Surgeons of England - August 10, 2020 Category: Surgery Authors: Cochrane E, Young S, Shariff Z Tags: Ann R Coll Surg Engl Source Type: research

Systematic review/meta-analysis on efficacy of allogeneic HCT in sickle cell disease: an international effort on behalf of the Pediatric Diseases Working Party of EBMT and the Sickle Cell Transplantation International Consortium
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy affecting nearly 100,000 individuals in the United States and approximately 300,000 worldwide, with low-income countries bearing the highest burden.1, 2 It is associated with several complications including debilitating morbidity, organ injury, and shortened life expectancy. Progress have been made in recent years to the overall management of SCD, namely improved health maintenance surveillance programs, penicillin prophylaxis, chronic blood transfusions, vaccines, primary and secondary stroke prophylaxis, use of hydroxyurea and approval of novel agent...
Source: Biology of Blood and Marrow Transplantation - December 10, 2020 Category: Hematology Authors: Madiha Iqbal, Tea Reljic, Selim Corbacioglu, Josu de la Fuente, Eliane Gluckman, Ambuj Kumar, Farah Yassine, Ernesto Ayala, Areej El-Jawahri, Hemant Murthy, Fahad Almohareb, Shahrukh K. Hashmi, Barbara Cappelli, Ali Alahmari, Graziana Maria Scigliuolo, Ad Source Type: research

Allogenic Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
Sickle cell disease (SCD) is one of the most common monogenic disorders worldwide and affects approximately 100,000 people in the United States alone. SCD can cause numerous complications, including anemia, pain, stroke, and organ failure, which can lead to death. Although there are a few disease-modifying treatments available to patients with SCD, the only current curative option is a hematopoietic stem cell transplant (HSCT). In this review, we will discuss the different approaches to allogeneic HSCT in the treatment of SCD and the outcomes of these approaches.
Source: Transfusion and Apheresis Science - January 10, 2021 Category: Hematology Authors: Dana K. Furstenau, John F. Tisdale Source Type: research

Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium
Sickle cell disease (SCD) is the most common inherited hemoglobinopathy, affecting nearly 100,000 individuals in the United States and approximately 300,000 worldwide, with low-income countries bearing the highest burden [1,2]. It is associated with several complications, including debilitating morbidity, organ injury, and shortened life expectancy. Progress in the overall management of SCD has been made in recent years, namely improved health maintenance surveillance programs, penicillin prophylaxis, chronic blood transfusions, vaccines, primary and secondary stroke prophylaxis, use of hydroxyurea, and approval of novel a...
Source: Biology of Blood and Marrow Transplantation - December 10, 2020 Category: Hematology Authors: Madiha Iqbal, Tea Reljic, Selim Corbacioglu, Josu de la Fuente, Eliane Gluckman, Ambuj Kumar, Farah Yassine, Ernesto Ayala, Areej El-Jawahri, Hemant Murthy, Fahad Almohareb, Shahrukh K. Hashmi, Barbara Cappelli, Ali Alahmari, Graziana Maria Scigliuolo, Ad Source Type: research

Hematopoietic Cell Transplant Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Sickle cell disease (SCD) is the most common inherited hemoglobin disorder affecting approximately 100,000 people in the United States (U.S.), a majority of whom are Black/African American, with an incidence rate of 1 in every 365 births.1 SCD is a chronic health condition associated with acute painful vaso-occlusive crisis (VOC), acute chest syndrome (ACS), stroke, chronic organ damage and culminates in a life expectancy that is less than half that of the general American population.2-4
Source: Biology of Blood and Marrow Transplantation - April 21, 2021 Category: Hematology Authors: Tatenda G. Mupfudze, Christa Meyer MS, Jaime M. Preussler, Lih-Wen Mau, Yung-Tsi Bolon, Patricia Steinert, Staci D. Arnold, Wael Saber, Lakshmanan Krishnamurti Source Type: research

Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Sickle cell disease (SCD) is the most common inherited hemoglobin disorder, affecting approximately 100,000 people in the United States, a majority of whom are Black/African American, with an incidence rate of 1 in every 365 births [1]. SCD is a chronic health condition associated with acute painful vaso-occlusive crisis (VOC), acute chest syndrome (ACS), stroke, and chronic organ damage and culminates in a life expectancy that is less than one-half that of the general American population [2 –4].
Source: Biology of Blood and Marrow Transplantation - April 21, 2021 Category: Hematology Authors: Tatenda G. Mupfudze, Christa Meyer, Jaime M. Preussler, Lih-Wen Mau, Yung-Tsi Bolon, Patricia Steinert, Staci D. Arnold, Wael Saber, Lakshmanan Krishnamurti Source Type: research

Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018
This report is the first comprehensive description of CDC's efforts in collaboration with participating states to establish, maintain, and expand SCD surveillance through the SCDC program to improve health outcomes for persons living with SCD. Findings from California and Georgia analyses highlighted a need for additional SCD specialty clinics. Despite different approaches, expansion of SCDC to multiple states was possible using standardized, rigorous methods developed across all participating states for reporting on disease prevalence, health care needs and use, and deaths.PUBLIC HEALTH ACTION: Findings from surveillance ...
Source: MMWR Surveill Summ - October 6, 2022 Category: Epidemiology Authors: Angela B Snyder Sangeetha Lakshmanan Mary M Hulihan Susan T Paulukonis Mei Zhou Sophia S Horiuchi Karon Abe Shammara N Pope Laura A Schieve Source Type: research